Qualigen Reports Multiple Corporate Actions: Agreements, Debt, Equity Sales, and Officer Changes
Ticker: AIXC · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $500,000, $550,000, $0.6111, $0.26, $1,100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, equity-sales, debt, management-change
TL;DR
**Qualigen just dropped an 8-K detailing new agreements, debt, equity sales, and officer changes, but the crucial specifics are missing!**
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on February 27, 2024, reporting multiple significant events that occurred on February 25, 2024. These events include the company entering into a material definitive agreement, creating a direct financial obligation, conducting unregistered sales of equity securities, and making changes to its directors or officers, including compensatory arrangements. Specific details regarding the parties involved, dollar amounts, or the nature of these agreements and changes are not provided in this excerpt.
Why It Matters
These reported events signal significant operational and financial shifts for Qualigen Therapeutics, potentially impacting its capital structure, governance, and future strategic direction, though the lack of specific details in this excerpt prevents a full assessment of their implications.
Risk Assessment
Risk Level: medium — The filing indicates multiple significant corporate actions, including new financial obligations and equity sales, whose specific terms are unknown, introducing uncertainty and potential risk.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — registrant
- RITTER PHARMACEUTICALS INC (company) — former company name
- February 25, 2024 (date) — date of earliest event reported
- February 27, 2024 (date) — filing date
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 25, 2024.
What type of company is Qualigen Therapeutics, Inc. according to its Standard Industrial Classification?
Qualigen Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
What were the main categories of events reported in this 8-K?
The main categories of events reported included entry into a material definitive agreement, creation of a direct financial obligation, unregistered sales of equity securities, and changes in directors or certain officers, including compensatory arrangements.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 27, 2024.
What was Qualigen Therapeutics, Inc.'s former company name?
Qualigen Therapeutics, Inc.'s former company name was RITTER PHARMACEUTICALS INC.
Filing Stats: 1,243 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2024-02-27 07:00:05
Key Financial Figures
- $500,000 — ay the Company a cash purchase price of $500,000 (less expenses). Pursuant to the Agre
- $550,000 — "Debenture") in the principal amount of $550,000. The Debenture would have a maturity da
- $0.6111 — ares of common stock of the Company, at $0.6111 per share, subject to adjustment as des
- $0.26 — warrant (the "Warrant") to purchase (at $0.26 per share – the "Exercise Price") 900,0
- $1,100,000 — purchase from the Company an additional $1,100,000 in principal amount of Debentures of li
- $1,000,000 — ts of like tenor, all for an additional $1,000,000 in cash (less expenses). The $0.26 ex
- $1,198,922 — held by Alpha, resulting in the current $1,198,922 principal amount thereof becoming conve
- $0.73 — arrants would have been exercisable (at $0.73 per share) pre-adjustment. Finally, the
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 297KB
- ex10-2.htm (EX-10.2) — 168KB
- ex10-3.htm (EX-10.3) — 123KB
- ex10-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-007928.txt ( ) — 945KB
- qlgn-20240225.xsd (EX-101.SCH) — 3KB
- qlgn-20240225_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240225_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: February 27, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer